Article

Ruboxistaurin results: Eli Lilly plans more trials

Indianapolis-Eli Lilly and Co. will delay the submission of its ruboxistaurin for the treatment of diabetic retinopathy and diabetic macular edema (DME) after two clinical trials failed to achieve satisfactory results on disease progression.

Related Videos
Related Content
Glaukos submits NDA to FDA for Epioxa
December 23rd 2024

Glaukos submits NDA to FDA for Epioxa

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Mental health and awareness gaps hinder diabetic eye screenings
December 23rd 2024

Mental health and awareness gaps hinder diabetic eye screenings

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Curacle presents results of its phase 2a clinical trial of CU06 for DME
December 20th 2024

Curacle presents results of its phase 2a clinical trial of CU06 for DME

Study validates long-term efficacy of MicroPulse TLT for glaucoma management
Published: December 19th 2024 | Updated: December 19th 2024

Study validates long-term efficacy of MicroPulse TLT for glaucoma management

© 2024 MJH Life Sciences

All rights reserved.